Earnings

Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate

Aug 13, 2026 · 08:58 AM ET· updated 1h ago

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share

Why It Matters

Ovid lost less money per share than experts thought it would, which is good news. When a company that's still losing money does better than people expected, it shows the business might be getting stronger.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OVID2.73

+0.11 (+4.35%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.